English

ABBOTT BIOTHERAPEUTICS CORP

EDGAR

Annual report amendment (10-K/A) · filed 2010-04-19

7 filing records in this dataset, filed from 2009-03-31 to 2010-04-19. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

15.1 million USD

2009-12-31 · USD

Exact inputs and evidence

Revenue: 46101000 USD Source
Revenue: 30998000 USD Source

Operating margin

-198.35%

2009-12-31 · %

Exact inputs and evidence

Operating Income: -143556000 USD Source
Operating Income: -113599000 USD Source
Revenue: 46101000 USD Source
Revenue: 30998000 USD Source

Operating cash flow

-21.7 million USD

2009-12-31 · USD

Exact inputs and evidence

Operating Cash Flow: -99493000 USD Source
Operating Cash Flow: -77762000 USD Source

Free cash flow

-21.8 million USD

2009-12-31 · USD

Exact inputs and evidence

Operating Cash Flow: -99493000 USD Source
Operating Cash Flow: -77762000 USD Source
Capital Expenditure: 631000 USD Source
Capital Expenditure: 551000 USD Source

Cash and cash equivalents: 33.6 million USD 2009-12-31 Source
Exact value

33593000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

46.1 million USD

2009-01-01 – 2009-12-31

Exact inputs and evidence

Revenue: 9599000 USD · 2009-01-01 – 2009-03-31 Source
Revenue: 10551000 USD · 2009-04-01 – 2009-06-30 Source
Revenue: 10848000 USD · 2009-07-01 – 2009-09-30 Source
Revenue: 46101000 USD · 2009-01-01 – 2009-12-31 Source
Revenue: 30998000 USD · 2009-01-01 – 2009-09-30 Source

Net income

-142 million USD

2009-01-01 – 2009-12-31

Exact inputs and evidence

Net income: -29172000 USD · 2009-01-01 – 2009-03-31 Source
Net income: -40849000 USD · 2009-04-01 – 2009-06-30 Source
Net income: -40915000 USD · 2009-07-01 – 2009-09-30 Source
Net income: -141670000 USD · 2009-01-01 – 2009-12-31 Source
Net income: -110936000 USD · 2009-01-01 – 2009-09-30 Source

Operating cash flow

-99.5 million USD

2009-01-01 – 2009-12-31

Exact inputs and evidence

Operating cash flow: -19969000 USD · 2009-01-01 – 2009-03-31 Source
Operating cash flow: -34193000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: -19969000 USD · 2009-01-01 – 2009-03-31 Source
Operating cash flow: -77762000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: -34193000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: -99493000 USD · 2009-01-01 – 2009-12-31 Source
Operating cash flow: -77762000 USD · 2009-01-01 – 2009-09-30 Source

Capital expenditure

631 thousand USD

2009-01-01 – 2009-12-31

Exact inputs and evidence

Capital expenditure: 106000 USD · 2009-01-01 – 2009-03-31 Source
Capital expenditure: 453000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 106000 USD · 2009-01-01 – 2009-03-31 Source
Capital expenditure: 551000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 453000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 631000 USD · 2009-01-01 – 2009-12-31 Source
Capital expenditure: 551000 USD · 2009-01-01 – 2009-09-30 Source

Free cash flow

-100 million USD

2009-01-01 – 2009-12-31

Exact inputs and evidence

Operating cash flow: -19969000 USD · 2009-01-01 – 2009-03-31 Source
Operating cash flow: -34193000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: -19969000 USD · 2009-01-01 – 2009-03-31 Source
Operating cash flow: -77762000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: -34193000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: -99493000 USD · 2009-01-01 – 2009-12-31 Source
Operating cash flow: -77762000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 106000 USD · 2009-01-01 – 2009-03-31 Source
Capital expenditure: 453000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 106000 USD · 2009-01-01 – 2009-03-31 Source
Capital expenditure: 551000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 453000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 631000 USD · 2009-01-01 – 2009-12-31 Source
Capital expenditure: 551000 USD · 2009-01-01 – 2009-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2010-04-19.

Financial data available through: 2009-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2009-12-31
Operating income: 4 of 11 periods available· newest 2009-12-31
Net income: 4 of 11 periods available· newest 2009-12-31
Operating cash flow: 4 of 11 periods available· newest 2009-12-31
Capital expenditure: 4 of 11 periods available· newest 2009-12-31
Total assets: 3 of 11 periods available· newest 2009-12-31
Total liabilities: 3 of 11 periods available· newest 2009-12-31
Current assets: 3 of 11 periods available· newest 2009-12-31
Current liabilities: 3 of 11 periods available· newest 2009-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2009-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+152.4%

Prior period

USD 18.26 million

2008-01-01 – 2008-12-31
Current period

USD 46.1 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

46101000 − 18263000 = 27838000 USD

18263000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
46101000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Year-over-year change in Revenue: 27838000 USD Concept: fundies:Revenue Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 46101000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#6679 Input fundies:Revenue: 18263000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#6679
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 20.14 million

Prior period

−USD 161.81 million

2008-01-01 – 2008-12-31
Current period

−USD 141.67 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

-141670000 − -161813000 = 20143000 USD

-161813000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
-141670000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Year-over-year change in Net income: 20143000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -141670000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7095 Input fundies:NetIncome: -161813000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7095
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 65.64 million

Prior period

−USD 165.13 million

2008-01-01 – 2008-12-31
Current period

−USD 99.49 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

-99493000 − -165128000 = 65635000 USD

-165128000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
-99493000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Year-over-year change in Operating cash flow: 65635000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -99493000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 Input fundies:OperatingCashFlow: -165128000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-83.4%

Prior period

USD 3.8 million

2008-01-01 – 2008-12-31
Current period

USD 631,000

2009-01-01 – 2009-12-31

Exact inputs and evidence

631000 − 3796000 = -3165000 USD

3796000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
631000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Year-over-year change in Capital expenditure: -3165000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 631000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 Input fundies:CapitalExpenditure: 3796000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2009 2009-01-01 – 2009-12-31

Revenue USD 46.1 million 100% of revenue
Operating costs Derived USD 189.66 million 411% of revenue
Operating income −USD 143.56 million −311% of revenue
Tax, interest and other Derived −USD 1.89 million −4.1% of revenue
Net income −USD 141.67 million −307% of revenue

Cash

Operating cash flow −USD 99.49 million −216% of revenue
Capital expenditure USD 631,000 1.4% of revenue
Free cash flow Derived −USD 100.12 million −217% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2006 Operating loss: operating costs were 463% of revenue.
2007 Operating loss: operating costs were 945% of revenue.
2008 Operating loss: operating costs were 976% of revenue.
2009 Operating loss: operating costs were 411% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2006 2006-01-01 – 2006-12-31	51417000	238210000 Derived	-186793000	-104000 Derived	-186689000	-155068000 Derived	Source 2006-01-01 – 2006-12-31: 51417000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -186793000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -186689000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: -123170000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 31898000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	26692000	252356000 Derived	-225664000	1633000 Derived	-227297000	-274257000 Derived	Source 2007-01-01 – 2007-12-31: 26692000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -225664000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -227297000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -181930000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 92327000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	18263000	178316000 Derived	-160053000	1760000 Derived	-161813000	-168924000 Derived	Source 2008-01-01 – 2008-12-31: 18263000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -160053000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -161813000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -165128000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 3796000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	46101000	189657000 Derived	-143556000	-1886000 Derived	-141670000	-100124000 Derived	Source 2009-01-01 – 2009-12-31: 46101000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -143556000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -141670000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -99493000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 631000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 46.1M 2009

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Revenue	51417000	Revenue: 51417000 Open source
20072007-12-31	Revenue	26692000	Revenue: 26692000 Open source
20082008-12-31	Revenue	18263000	Revenue: 18263000 Open source
20092009-12-31	Revenue	46101000	Revenue: 46101000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

152.4% 2009

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20062006-12-31	Year over year	No prior comparable period	Revenue: 51417000 Open source
20072007-12-31	Year over year	-48.1%	Revenue: 26692000 Open source Revenue: 51417000 Open source
20082008-12-31	Year over year	-31.6%	Revenue: 18263000 Open source Revenue: 26692000 Open source
20092009-12-31	Year over year	152.4%	Revenue: 46101000 Open source Revenue: 18263000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -311.4% 2009

Net margin -307.3% 2009

Free cash flow margin -217.2% 2009

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20062006-12-31	Operating margin	-363.3%	Operating Income: -186793000 Open source Revenue: 51417000 Open source
20072007-12-31	Operating margin	-845.4%	Operating Income: -225664000 Open source Revenue: 26692000 Open source
20082008-12-31	Operating margin	-876.4%	Operating Income: -160053000 Open source Revenue: 18263000 Open source
20092009-12-31	Operating margin	-311.4%	Operating Income: -143556000 Open source Revenue: 46101000 Open source
20062006-12-31	Net margin	-363.1%	Net Income: -186689000 Open source Revenue: 51417000 Open source
20072007-12-31	Net margin	-851.6%	Net Income: -227297000 Open source Revenue: 26692000 Open source
20082008-12-31	Net margin	-886%	Net Income: -161813000 Open source Revenue: 18263000 Open source
20092009-12-31	Net margin	-307.3%	Net Income: -141670000 Open source Revenue: 46101000 Open source
20062006-12-31	Free cash flow margin	-301.6%	Revenue: 51417000 Open source Operating Cash Flow: -123170000 Open source Capital Expenditure: 31898000 Open source
20072007-12-31	Free cash flow margin	-1,027.5%	Revenue: 26692000 Open source Operating Cash Flow: -181930000 Open source Capital Expenditure: 92327000 Open source
20082008-12-31	Free cash flow margin	-925%	Revenue: 18263000 Open source Operating Cash Flow: -165128000 Open source Capital Expenditure: 3796000 Open source
20092009-12-31	Free cash flow margin	-217.2%	Revenue: 46101000 Open source Operating Cash Flow: -99493000 Open source Capital Expenditure: 631000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -99.5M 2009

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Operating cash flow	-123170000	Operating Cash Flow: -123170000 Open source
20072007-12-31	Operating cash flow	-181930000	Operating Cash Flow: -181930000 Open source
20082008-12-31	Operating cash flow	-165128000	Operating Cash Flow: -165128000 Open source
20092009-12-31	Operating cash flow	-99493000	Operating Cash Flow: -99493000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -100.1M 2009

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20062006-12-31	Free cash flow	-155068000	Operating Cash Flow: -123170000 Open source Capital Expenditure: 31898000 Open source
20072007-12-31	Free cash flow	-274257000	Operating Cash Flow: -181930000 Open source Capital Expenditure: 92327000 Open source
20082008-12-31	Free cash flow	-168924000	Operating Cash Flow: -165128000 Open source Capital Expenditure: 3796000 Open source
20092009-12-31	Free cash flow	-100124000	Operating Cash Flow: -99493000 Open source Capital Expenditure: 631000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

27.6% 2009

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2006-12-31	Liabilities / assets	Not reported	No source recorded
20072007-12-31	Liabilities / assets	28.8%	Total Liabilities: 106386000 Open source Total Assets: 369066000 Open source
20082008-12-31	Liabilities / assets	19%	Total Liabilities: 102388000 Open source Total Assets: 538021000 Open source
20092009-12-31	Liabilities / assets	27.6%	Total Liabilities: 117101000 Open source Total Assets: 423624000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.92× 2009

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2006-12-31	Current assets / current liabilities	Not reported	No source recorded
20072007-12-31	Current assets / current liabilities	0.61×	Current Assets: 29894000 Open source Current Liabilities: 48890000 Open source
20082008-12-31	Current assets / current liabilities	19.18×	Current Assets: 416993000 Open source Current Liabilities: 21737000 Open source
20092009-12-31	Current assets / current liabilities	8.92×	Current Assets: 317346000 Open source Current Liabilities: 35557000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2006 2006-01-01 – 2006-12-31	−USD 186.69 million Exact value Exact value: -186689000 USD 2006-01-01 – 2006-12-31: -186689000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABBOTT BIOTHERAPEUTICS CORP · 2006-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Net Income: -186689000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -186689000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-09-003430.txt#6103 The citation records this snapshot. The page link may show a newer release later.	−USD 123.17 million Exact value Exact value: -123170000 USD 2006-01-01 – 2006-12-31: -123170000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABBOTT BIOTHERAPEUTICS CORP · 2006-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Operating Cash Flow: -123170000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -123170000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-09-003430.txt#6431 The citation records this snapshot. The page link may show a newer release later.	USD 31.9 million Exact value Exact value: 31898000 USD 2006-01-01 – 2006-12-31: 31898000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABBOTT BIOTHERAPEUTICS CORP · 2006-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Capital Expenditure: 31898000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 31898000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-09-003430.txt#6482 The citation records this snapshot. The page link may show a newer release later.	−USD 155.07 million Calculation and evidence -123170000 − 31898000 USD Exact free cash flow: -155068000 USD 2006-01-01 – 2006-12-31: -123170000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 31898000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABBOTT BIOTHERAPEUTICS CORP · 2006-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Free cash flow: -155068000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -123170000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-09-003430.txt#6431 Input fundies:CapitalExpenditure: 31898000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-09-003430.txt#6482 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	−USD 227.3 million Exact value Exact value: -227297000 USD 2007-01-01 – 2007-12-31: -227297000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABBOTT BIOTHERAPEUTICS CORP · 2007-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Net Income: -227297000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -227297000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7095 The citation records this snapshot. The page link may show a newer release later.	−USD 181.93 million Exact value Exact value: -181930000 USD 2007-01-01 – 2007-12-31: -181930000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABBOTT BIOTHERAPEUTICS CORP · 2007-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Operating Cash Flow: -181930000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -181930000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 The citation records this snapshot. The page link may show a newer release later.	USD 92.33 million Exact value Exact value: 92327000 USD 2007-01-01 – 2007-12-31: 92327000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABBOTT BIOTHERAPEUTICS CORP · 2007-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Capital Expenditure: 92327000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 92327000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.	−USD 274.26 million Calculation and evidence -181930000 − 92327000 USD Exact free cash flow: -274257000 USD 2007-01-01 – 2007-12-31: -181930000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 92327000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABBOTT BIOTHERAPEUTICS CORP · 2007-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Free cash flow: -274257000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -181930000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 Input fundies:CapitalExpenditure: 92327000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 161.81 million Exact value Exact value: -161813000 USD 2008-01-01 – 2008-12-31: -161813000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABBOTT BIOTHERAPEUTICS CORP · 2008-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Net Income: -161813000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -161813000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7095 The citation records this snapshot. The page link may show a newer release later.	−USD 165.13 million Exact value Exact value: -165128000 USD 2008-01-01 – 2008-12-31: -165128000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABBOTT BIOTHERAPEUTICS CORP · 2008-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Operating Cash Flow: -165128000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -165128000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 The citation records this snapshot. The page link may show a newer release later.	USD 3.8 million Exact value Exact value: 3796000 USD 2008-01-01 – 2008-12-31: 3796000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABBOTT BIOTHERAPEUTICS CORP · 2008-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Capital Expenditure: 3796000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3796000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.	−USD 168.92 million Calculation and evidence -165128000 − 3796000 USD Exact free cash flow: -168924000 USD 2008-01-01 – 2008-12-31: -165128000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 3796000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABBOTT BIOTHERAPEUTICS CORP · 2008-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Free cash flow: -168924000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -165128000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 Input fundies:CapitalExpenditure: 3796000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 141.67 million Exact value Exact value: -141670000 USD 2009-01-01 – 2009-12-31: -141670000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Net Income: -141670000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -141670000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7095 The citation records this snapshot. The page link may show a newer release later.	−USD 99.49 million Exact value Exact value: -99493000 USD 2009-01-01 – 2009-12-31: -99493000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Operating Cash Flow: -99493000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -99493000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 The citation records this snapshot. The page link may show a newer release later.	USD 631,000 Exact value Exact value: 631000 USD 2009-01-01 – 2009-12-31: 631000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Capital Expenditure: 631000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 631000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.	−USD 100.12 million Calculation and evidence -99493000 − 631000 USD Exact free cash flow: -100124000 USD 2009-01-01 – 2009-12-31: -99493000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 631000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABBOTT BIOTHERAPEUTICS CORP · 2009-12-31 ABBOTT BIOTHERAPEUTICS CORP (edgar:1441848) Free cash flow: -100124000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T23:56:05Z Snapshot: 71150e9eb7a695930af060642d9f783c5eb3854d592bc124a21e976cc770e818 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441848?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -99493000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7407 Input fundies:CapitalExpenditure: 631000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441848/0001047469-10-001170.txt#7472 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

7 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001441848, 1441848, edgar:1441848

Also known as Biotech Spinco, Inc., FACET BIOTECH CORP

ABBOTT BIOTHERAPEUTICS CORP

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2009 2009-01-01 – 2009-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation